These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 25810549)

  • 1. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
    Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
    J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
    Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
    J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
    Price AM; Messinger JE; Luftig MA
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
    Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway.
    Gatto G; Rossi A; Rossi D; Kroening S; Bonatti S; Mallardo M
    Nucleic Acids Res; 2008 Nov; 36(20):6608-19. PubMed ID: 18940871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
    Martin KA; Lupey LN; Tempera I
    J Virol; 2016 Oct; 90(19):8520-30. PubMed ID: 27440880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
    Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway.
    Wang L; Howell MEA; Sparks-Wallace A; Zhao J; Hensley CR; Nicksic CA; Horne SR; Mohr KB; Moorman JP; Yao ZQ; Ning S
    mBio; 2021 Oct; 12(5):e0109721. PubMed ID: 34488443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.
    Goormachtigh G; Ouk TS; Mougel A; Tranchand-Bunel D; Masy E; Le Clorennec C; Feuillard J; Bornkamm GW; Auriault C; Manet E; Fafeur V; Adriaenssens E; Coll J
    J Virol; 2006 Aug; 80(15):7382-93. PubMed ID: 16840319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
    Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent membrane protein 1 of Epstein-Barr virus regulates death-associated protein kinase 1 in lymphoblastoid cell line.
    Lee CW; Leu SJ; Tzeng RY; Wang SF; Tsai SC; Sun KH; Chen RH; Huang JC
    Virology; 2011 Apr; 413(1):19-25. PubMed ID: 21353277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.
    Price AM; Tourigny JP; Forte E; Salinas RE; Dave SS; Luftig MA
    J Virol; 2012 Oct; 86(20):11096-106. PubMed ID: 22855490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
    Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
    J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
    Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
    Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
    Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
    J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.
    Konforte D; Simard N; Paige CJ
    Virology; 2008 Apr; 374(1):100-13. PubMed ID: 18222514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
    Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
    Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.